RT Journal Article
T1 Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable.
T2 Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD.
A1 Miravitlles, Marc
A1 Calle, Myriam
A1 Molina, Jesus
A1 Almagro, Pere
A1 Gomez, Jose-Tomas
A1 Trigueros, Juan Antonio
A1 Cosio, Borja G
A1 Casanova, Ciro
A1 Lopez-Campos, Jose Luis
A1 Riesco, Juan Antonio
A1 Simonet, Pere
A1 Rigau, David
A1 Soriano, Joan B
A1 Ancochea, Julio
A1 Soler-Cataluña, Juan Jose
K1 COPD
K1 Control
K1 EPOC
K1 Fenotipos
K1 Guidelines
K1 Normativa
K1 Phenotypes
K1 Tratamiento
K1 Treatment
AB The Spanish COPD Guidelines (GesEPOC) were first published in 2012, and since then have undergone a series of updates incorporating new evidence on the diagnosis and treatment of COPD. GesEPOC was drawn up in partnership with scientific societies involved in the treatment of COPD and the Spanish Patients' Forum. Their recommendations are based on an evaluation of the evidence using GRADE methodology, and a narrative description of the evidence in areas in which GRADE cannot be applied. In this article, we summarize the recommendations on the pharmacological treatment of stable COPD based on 9 PICO questions. COPD treatment is a 4-step process: 1) diagnosis, 2) determination of the risk level, 3) initial and subsequent inhaled therapy, and 4) identification and management of treatable traits. For the selection of inhaled therapy, high-risk patients are divided into 3 phenotypes: non-exacerbator, eosinophilic exacerbator, and non-eosinophilic exacerbator. Some treatable traits are general and should be investigated in all patients, such as smoking or inhalation technique, while others affect severe patients in particular, such as chronic hypoxemia and chronic bronchial infection. COPD treatment is based on long-acting bronchodilators with single agents or in combination, depending on the patient's risk level. Eosinophilic exacerbators must receive inhaled corticosteroids, while non-eosinophilic exacerbators require a more detailed evaluation to choose the best therapeutic option. The new GesEPOC also includes recommendations on the withdrawal of inhaled corticosteroids and on indications for alpha-1 antitrypsin treatment. GesEPOC offers a more individualized approach to COPD treatment tailored according to the clinical characteristics of patients and their level of complexity.
PB Elsevier Doyma
YR 2022
FD 2022
LK http://hdl.handle.net/10668/21982
UL http://hdl.handle.net/10668/21982
LA en
LA es
NO Miravitlles M, Calle M, Molina J, Almagro P, Gómez JT, Trigueros JA, et al. Actualización 2021 de la Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable.. 2022 Jan;58(1):69-81. English, Spanish.
DS RISalud
RD Apr 5, 2025